Inconsistent reporting of adverse drug reactions to anti-malarials
29 Ene 2015
WWARN Published Date
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-fareast-language:EN-US;}
The latest issue of Malaria Journal includes an assessment of the pharmacovigilance reporting of all anti-malarials, including artemisinin combination therapies (ACTs), to the WHO adverse drug reaction (ADR) database over the past 40 years.
The paper illustrates the low reporting of ADRs to anti-malarials in general and ACTs in particular. Most reports were submitted by non-endemic and/or high-income countries. The author concludes that the presence of well functioning national pharmacovigilance systems is vital to ensure safe and responsible scale up of ACT deployment.
Click here to read the full article.